Background
During 2014, Cuban refugees were the fifth largest group to resettle in the United States; Texas resettled the second largest number of Cuban refugees [1] . In addition, through the U.S. Cuban-Haitian Entrant Program, Cubans are allowed to enter the United States as parolees and are eligible for refugee benefits and services administered by the Office of Refugee Resettlement [2] .
Upon arrival to the United States, refugees and parolees are recommended to undergo a post-arrival health assessment within the first 90 days [3] . CDC recommends that HepB vaccination be offered to all newly arrived refugees who are not infected and non-immune based on serologic testing, and considered at high risk for infection. In addition, if a partial vaccine series is documented despite antibody to HBsAg (anti-HBs) positivity, the vaccine series should be completed based on the Advisory Committee on Immunization Practices (ACIP)-recommended schedule [4] .
In recent years, the Texas Department of State Health Services Refugee Health Program reported inconsistencies between the overseas HepB vaccination information and the HBV serologic testing results among newly arrived Cubans. Specifically, some persons, with a completed series of HepB vaccinations documented on the overseas records, had decreased response (i.e., anti-HBs <10 mIU/mL) to HBV according to serology results. In this evaluation, we assessed the overseas HepB vaccination documentation and [5] . Qualitative serologic HBV test results comprised of the HepB surface antigen (HBsAg) test, antibody to HepB core antigen (anti-HBc) and anti-HBs. Anti-HBs ≥10 mIU/mL is considered a correlate of vaccine-induced protection for persons who have completed an approved vaccination series [6] . Interpretation of the serologic tests [6] were as follows- (1) Valid documented overseas doses were assessed based on the ACIP recommended schedule [4] and defined as-(1) the second dose at a minimum of 4 weeks after the first dose; (2) the third dose at least 8 weeks after the second dose and 16 weeks after the first dose; and (3) the third and final dose administered no earlier than 24 weeks of age.
We categorized persons into five age groups (<5, 5-18, 19-39, 40-59, and ≥60 years), and classified overseas documented doses as: (1) no dose, (2) 1-2 doses, and (3) 3 doses or more. We calculated the number and proportion of people in each of the four serologic testing categories by overseas doses and by age category.
This assessment was determined non-research by the CDC's Human Subject Advisors. The Refugee Health Program of the Texas Department of State Health Services approved the use of these data for analysis.
Results
Of 10,937 newly arrived Cubans in Texas, 8814 (80.6%) were excluded from the analysis because there were no corresponding overseas HepB vaccination records. Of the 8814 excluded, 8650 (98%) were Cubans determined to be a parolee at the U.S. port of entry [7] and did not have any overseas vaccination records. Of the remaining 2123 persons with an overseas HepB vaccination record and domestic HBV serologic test, 1085 (51.2%) were female, 591 (27.8%) were children <19 years of age, and 1022 (48.1%) had a parolee visa type prior to arrival in the US (Table 1) . Of the 2123 people with vaccination records, 711 (33.5%) had no documented HepB doses, 340 (16%) had 1-2 doses, and 1072 (50.5%) had 3 doses (Table 1) . Of those with no (Table 1) . Immunity for those with three overseas HepB doses were greatest for those <5 years (87.5%), but decreased with age (51.2% for those 40-59 years and 10.6% for those ≥60 years) ( Table 2 ).
Discussion
Our findings confirm reports of no or low anti-HBs serologic results among newly arrived Cubans in Texas. HBV protection has been reported >90% after three intramuscular doses of the HepB vaccine and serologic response decreases with age; seroprotection is achieved in approximately 95% of healthy infants, approximately 92% of health-care personnel aged <40 years, and approximately 84% of health-care personnel aged ≥40 years [8] . The newly arrived Cubans in our assessment were last vaccinated on average 11.4 (95% CI 10.9-11.9) years prior to arrival in the U.S. (data not shown). When we analyzed those with three documented doses with last vaccination date prior to arrival, there was no significant difference in immunity due to HBV vaccination between those who were last vaccinated between 0 and 5 years and >20 years prior to arrival, 37% (95% CI 31.6-42.9) and 37.4% (95% CI 29.1-46.5) respectively. Lastly, the children who were more recently vaccinated prior to arrival showed greater response.
The waning of anti-HBs has been reported previously. Leurdian et al. [9] provide several reviews of studies showing long-term protection is present despite a decrease in anti-HBs over time. A 30-year follow-up study and response to a challenge dose among Alaskan Native adults and children found 51% with positive anti-HBs response, and among those with negative anti-HBs response, 88% expressed an anti-HBs response 30 days after a challenge dose [10] .
We found that the newly arrived Cubans showed low HBV infection rates (0.7%) among those vaccinated which is comparable to previous studies. The prevalence of HBsAg positive among Cubans who arrived during 2006-2008 was 1% (95% CI 0.8-1.1) [11] and 0.9% (95% CI 0.6-1.1) among Cuban-born living in the U.S. [12] . Also, when we assessed all available domestic HBV serologic results among all newly arrived Cubans in Texas (N = 10,937), of which most were adults (86.6%), the HBV infection rates of the Cuban cohort was similar to the U.S. population based on National Health and Nutrition Examination Survey (NHANES) 2012 analysis [13] -0.5% (95% CI 0.4-0.6) versus 0.3% (95% CI 0.2-0.4), respectively. Also, the Cuban cohort had a greater population immunity from HepB vaccination than the U.S. data used in the NHANES analysis-39.3% (95% CI 38.4-40.2) versus 25.1% (95% CI 24.1-26.1), respectively [13] .
In summary, our findings concur with previous observations that anti-HBs serologic results wane over time. Although an additional HepB vaccine dose for newly arrived Cubans with completed documented doses on the U.S. Department of States forms can be given, these individuals might be protected, if consistent with previous studies showing long lasting cellular immunity in healthy persons despite waning anti-HBs levels. 
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